journal article·2023-07-26

Tumor-Associated Macrophages Regulating a Polymer Nanoplatform for Synergistic Treatment of Breast Tumors

Li Zhang, Shuai Cui, Ning Ding, Jing Zhang, Enna Cui, Qian Xiang, Zhenghao Zhou, Bo Sun, Yinan Wang, Hao Hong, Yunsu Ma, Dongzhi Yang

ACS Applied Materials & Interfaces· Volume 15· Issue 29
Publisher page

Abstract

Tumor-associated macrophages (TAMs) play a critical role in tumor progression and metastasis. Modulation of TAM polarization is one of the most effective strategies to change the immunosuppressive tumor microenvironment (TME). In this study, organic polymer nanoparticles (CPHT) were prepared using hyaluronic acid (HA)-conjugated disulfide-bonded polyethylene imide (PEIS) as a carrier through a self-assembly strategy. These nanoparticles were modified by transferrin (Tf) and loaded with chlorin e6 (Ce6). The results showed that CPHT had good dispersion with a particle size of about 30 nm. CPHT gradually disintegrated under the exposure with a high concentration of glutathione (GSH) in tumor cells, proving the possibility for the controlled release of Ce6 and photodynamic therapy. An in vitro test showed that the uptake of CPHT in tumor cells was mediated by both HA and Tf, indicating the active tumor-targeting capacity of CPHT. CPHT significantly downregulated the ratio of CD206/CD86 and triggered the upregulation of immune factors such as TNF-α and iNOS, suggesting the repolarization of TAMs. We also found that CPHT effectively induced ferroptosis in tumor cells through lipid peroxide accumulation, GSH depletion, and downregulation of lipid peroxidase (GPX4) expression. Animal experiments confirmed that CPHT not only effectively inhibited the growth of tumors in situ but also significantly decelerated the growth of the distal tumor. Elevated levels of CD86 and IFN-γ and decreased expression of CD206 were observed at the tumor sites post CPHT treatment. These results confirmed the value of CPHT as a multifunctional nanoplatform that can tune the TME and provide new hope for tumor treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, PR China

State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu 210093, PR China

Jiangsu Yuanlong Hospital Management Co. LTD, Xuzhou, Jiangsu 221000, PR China

Funding

Qinglan Project of Jiangsu Province of China · Natural Science Foundation of Jiangsu Province · High Level Innovation and Entrepreneurial Research Team Program in Jiangsu · Xuzhou Science and Technology Program · Jiangsu Graduate Scientific Research Innovation Project · Xuzhou Medical University Science Park

References (45)

Show source-provided references
1. 10.1021/acsnano.9b0328810.1021/acsnano.9b03288 ↗
2. 10.1021/acsnano.5b0677910.1021/acsnano.5b06779 ↗
3. 10.1016/j.jconrel.2011.11.01310.1016/j.jconrel.2011.11.013 ↗
4. 10.1016/j.bioactmat.2020.12.01010.1016/j.bioactmat.2020.12.010 ↗
5. 10.1016/j.cub.2020.01.03110.1016/j.cub.2020.01.031 ↗
6. 10.3389/fimmu.2020.58308410.3389/fimmu.2020.583084 ↗
7. 10.1002/ctm2.28810.1002/ctm2.288 ↗
8. 10.1016/j.cmet.2019.06.00110.1016/j.cmet.2019.06.001 ↗
9. 10.1136/jitc-2020-00134110.1136/jitc-2020-001341 ↗
10. 10.1186/s13046-018-0792-510.1186/s13046-018-0792-5 ↗
11. 10.1021/acsnano.1c0210310.1021/acsnano.1c02103 ↗
12. 10.1016/j.bbrc.2018.09.09710.1016/j.bbrc.2018.09.097 ↗
13. 10.1021/acsbiomaterials.5b0018110.1021/acsbiomaterials.5b00181 ↗
14. 10.1002/jbm.a.3276010.1002/jbm.a.32760 ↗
15. 10.2147/ott.s18097210.2147/ott.s180972 ↗
16. 10.3109/1061186x.2015.105207210.3109/1061186x.2015.1052072 ↗
17. 10.1016/j.carbpol.2016.08.02110.1016/j.carbpol.2016.08.021 ↗
18. 10.7150/thno.3314110.7150/thno.33141 ↗
19. 10.1039/d0tb02360d10.1039/d0tb02360d ↗
20. 10.1155/2016/605814710.1155/2016/6058147 ↗
21. 10.1021/acsnano.8b0763510.1021/acsnano.8b07635 ↗
22. 10.1002/med.1000810.1002/med.10008 ↗
23. 10.1039/d0nh00674b10.1039/d0nh00674b ↗
24. 10.2174/138161282266616102616234710.2174/1381612822666161026162347 ↗
25. 10.1002/jbm.a.3528610.1002/jbm.a.35286 ↗
26. 10.1016/j.addr.2020.05.00510.1016/j.addr.2020.05.005 ↗
27. 10.1016/j.ijbiomac.2019.07.01410.1016/j.ijbiomac.2019.07.014 ↗
28. 10.1002/adma.20140387710.1002/adma.201403877 ↗
29. 10.31768/2312-8852.2015.37(4):250-25410.31768/2312-8852.2015.37(4):250-254 ↗
30. 10.1021/acs.molpharmaceut.7b0054810.1021/acs.molpharmaceut.7b00548 ↗
31. 10.1016/j.biomaterials.2012.12.05110.1016/j.biomaterials.2012.12.051 ↗
32. 10.1016/s1359-6446(04)03333-110.1016/s1359-6446(04)03333-1 ↗
33. 10.1016/j.ejps.2015.11.00910.1016/j.ejps.2015.11.009 ↗
34. 10.1016/j.ab.2010.12.02610.1016/j.ab.2010.12.026 ↗
35. 10.1002/adma.20160219710.1002/adma.201602197 ↗
36. 10.1038/s41467-017-00231-110.1038/s41467-017-00231-1 ↗
37. 10.1038/ni.192010.1038/ni.1920 ↗
38. National Research Council · 2011
39. 10.1016/j.carbpol.2019.11503310.1016/j.carbpol.2019.115033 ↗
40. 10.1002/pmic.20180031110.1002/pmic.201800311 ↗
41. 10.1002/smll.20200125110.1002/smll.202001251 ↗
42. 10.1016/j.biomaterials.2009.09.02410.1016/j.biomaterials.2009.09.024 ↗
43. 10.1021/acsami.9b2244010.1021/acsami.9b22440 ↗
44. 10.1021/acsami.0c1490910.1021/acsami.0c14909 ↗
45. 10.1002/adma.20170400710.1002/adma.201704007 ↗